Comparison of therapeutic effects of combination therapy with prednisolone and tacrolimus or azathioprine on progressive interstitial pneumonia with systemic sclerosis

We retrospectively compared the therapeutic effects of combination therapy with prednisolone (PSL) and oral tacrolimus (TAC) or azathioprine (AZA) on progressive interstitial pneumonia with systemic sclerosis (SSc-PIP). The effects of PSL (0.2-0.5 mg/kg/day) and TAC (3 mg/day) or AZA (1-2 mg/kg/day)...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2022-02, Vol.ahead-of-print (ahead-of-print), p.1-7
Main Authors: Kiboshi, Takao, Kotani, Takuya, Konma, Junichi, Makino, Hidehiko, Matsuda, Shogo, Suzuka, Takayasu, Wada, Yumiko, Shiba, Hideyuki, Hata, Kenichiro, Shoda, Takeshi, Takeuchi, Tohru
Format: Article
Language:English
Subjects:
azathioprine
Azathioprine - therapeutic use
Drug Therapy, Combination
Fibrosis
Humans
Immunosuppressive Agents - therapeutic use
interstitial pneumonia
Lung Diseases, Interstitial - complications
Lung Diseases, Interstitial - drug therapy
Prednisolone - therapeutic use
Retrospective Studies
Scleroderma, Systemic - complications
Scleroderma, Systemic - drug therapy
Systemic sclerosis
tacrolimus
Tacrolimus - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We retrospectively compared the therapeutic effects of combination therapy with prednisolone (PSL) and oral tacrolimus (TAC) or azathioprine (AZA) on progressive interstitial pneumonia with systemic sclerosis (SSc-PIP). The effects of PSL (0.2-0.5 mg/kg/day) and TAC (3 mg/day) or AZA (1-2 mg/kg/day) therapies (n = 18) were evaluated for short (12 months) and long (36 months or more) periods. In the short period, IP improved in 6 and 5 patients and was stable in 12 and 13 patients in the TAC and AZA groups, respectively. In the long period, 11 patients were followed up in the TAC group and 12 in the AZA group. IP improved in 4 and 2 patients and was stable in seven and nine in the TAC and AZA groups, respectively. The rates of evolution of total fibrosis score, and those corrected by disease duration for the long period, in the TAC group were significantly lower than those in the AZA group (p = .017 and .025, respectively). The inhibitory effect of PSL and TAC combination therapy on the progression of fibrosis in SSc-PIP may be superior to that of PSL and AZA in the long period.
ISSN:1439-7595
1439-7609
DOI:10.1080/14397595.2021.1918864